Drug Development

A new pharma deal isn't just about medicine. It's about the AI-driven network set to dismantle the slow, costly system of drug discovery as we know it.

With compelling Phase 2b survival data, NeuroSense is advancing its multi-target ALS drug to a pivotal Phase 3 trial. A deep dive into the science and strategy.

Prolium Bioscience advances its T-cell engager, PRO-203, in trials for scleroderma and lupus, heralding a new, potent strategy against severe autoimmunity.

Praxis Precision Medicines' elsunersen earns Breakthrough Therapy status, signaling a major step toward the first disease-modifying treatment for SCN2A-DEE.

Australian radiopharma innovator AdvanCell is planting its flag in Greater Boston with a new HQ and factory, a strategic move to scale its potent Lead-212 therapy.

bioAffinity Technologies' new gene-silencing therapy kills common skin cancer cells in lab studies while leaving healthy cells untouched, hinting at a future without scars.

Fueled by a family's legacy, the Preeclampsia Foundation's new funding seeks to solve the deadly puzzle of this pregnancy disorder and save mothers and babies.

With a key NSF grant and promising large-animal data, Endure Biotherapeutics' engineered 'native' bacteria may rewrite the playbook for PKU and beyond.

With new funding from top VCs, DropGenie is shrinking gene editing to power the next wave of AI-driven drug discovery using precious patient cells.

MapLight's Phase 2 trial for ASD missed its primary goal, but a powerful signal in reducing irritability in teens could reshape its future and offer a safer alternative.

A single drug receptor could treat cancer, psoriasis, and liver disease. Can-Fite’s new scientific validation boosts its platform, but clinical and financial hurdles loom.

A Chinese AI innovator and a new European biotech just sealed a massive deal. It’s a blueprint for the future of medicine, where technology and strategy unite for patients.

A new prostate cancer drug is emerging from a powerful alliance. We deconstruct the strategic rationale behind the deal, revealing a model for the future.

Merck's positive Phase 3 results for tulisokibart signal a new era for UC care, targeting both fibrosis and inflammation in a potential first-in-class win.

Israel's Biond Biologics hires Dr. Giovanni Selvaggi, a seasoned drug developer, as CMO. The move signals a strategic shift to accelerate its unique 'first-in-class' immunotherapies through late-stage trials.

With FDA clearance for its first-in-class remyelination drug, Scottish biotech Pheno Therapeutics is moving beyond inflammation to repair neurological damage.

Genialis's new BioBridge platform uses AI to de-risk the $137B flow of oncology drugs from China to the West, a critical test of resilience.

Sanofi taps AI-native biotech expert Paulo Fontoura to lead its global R&D, a high-stakes move to accelerate drug discovery after recent pipeline disappointments.

With a seasoned regulatory expert at the helm, Arletta Pharma is betting on its dual-action therapy, Lybrido, to transform the underserved FSIAD market.

A strategic pharma alliance scores a major win in Japan's lucrative neurology market, signaling a new competitive front and hope for thousands of patients.